Click here to take the survey on Improving PMS outcomes.
Canadian researchers have proposed six criteria that must be met for a disease-modifying therapy (DMT) to be effective in progressive multiple sclerosis (Yong & Yong. Nat Rev Neurol 2022;18:40-55). Over a dozen DMTs are currently available but they generally have limited effectiveness in slowing the neurodegeneration that underlies disability progression.
A number of new studies have provided data on the long-term safety and efficacy of high-efficacy disease-modifying therapies in MS. The data were presented at the American Academy of Neurology (AAN) annual meeting, held April 2-7 in Seattle, Washington. The following is a summary of key studies. Read More
Click here to watch Dr. Daniel Selchen discuss the case and the responses to the survey.
Kay, 39 years old, is sales clerk at a downtown department store. In 2009, at age 27 years, she was diagnosed with RRMS. Her initial presentation was optic neuritis, but she subsequently developed brainstem symptoms, including mild vertigo and difficulty swallowing. There was no family history of demyelinating or autoimmune disorders. There was no significant medical history and no comorbidities. Read More
A number of recent studies have reported on the incidence of acute neurological complications of COVID-19 infection, as well as long-term complications, variously called PASC (post-acute sequelae of COVID-19) or ‘long COVID’. Data were reported at the American Academy of Neurology annual meeting, held April 2-7 in Seattle, Washington. Read More